The Bone-parathyroid Crosstalk in Primary Hyperparathyroidism
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorI.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
About this trial
The PARABONE study aims to investigate the interaction between bone and parathyroid glands in patients with primary hyperparathyroidism (HPT). The study consists of a clinical part aimed at evaluating a series of circulating molecules of bone derivation (osteocalcin, molecules of the WNT pathway, RANKL, osteoprotegerin, Scelrostin, FGF23) in patients with HPT. In particular, the study has as its primary objective to identify the correlation between circulating levels of PTH and levels of GlaOC and GluOC in patients with HPT.
Eligibility criteria
Qualifiers
diagnosis of primary hyperparathyroidism according to the most recent guidelines [Marcocci et al. 2015];
adult patients (age ≥ 18 years);
signature of the informed consent.
diagnosis of primary hyperparathyroidism with indication of surgical removal of the parathyroid tumor according to the most recent guidelines [Marcocci et al. 2015];
Disqualifiers
age <18 years
diagnosis of hyperparathyroidism secondary to chronic renal failure or to vitamin D or calcium deficiency;
pregnancy or breastfeeding (self-declaration)
lack of informed consent
Trial design
Treatments tested in this trial
- Biomarker assays
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov